REGENXBIO Inc. (RGNX)

Name: REGENXBIO Inc. (RGNX) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001590877 · Nasdaq · Biological Products, (No Diagnostic Substances)

Sector Manufacturing
Fiscal year ends Dec 31

For the year ended 2025-12-31, REGENXBIO Inc. reported revenue of $170.44M. Revenue grew 104.5% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $174.48M.

Key ratios (year ended 2025-12-31)

-94.6%

Operating margin

-113.8%

Net margin

-188.7%

Return on year-end equity

104.5%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-16

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$174.48M	$170.44M	$83.33M	$90.24M	$112.72M	$470.35M	$154.57M	$35.23M	$218.50M	$10.39M	$4.59M
Cost of Revenue	n/a	n/a	$33.57M	$37.21M	$54.55M	$51.83M	$35.71M	$8.24M	$9.64M	$1.71M	n/a
Gross Profit (computed)	n/a	n/a	$49.76M	$53.03M	$58.18M	$418.51M	$118.85M	$26.99M	n/a	$8.68M	n/a
R&D Expense	$229.14M	$228.30M	$208.52M	$232.27M	$242.45M	$181.44M	$166.29M	$124.19M	$83.87M	$57.22M	$45.48M
Operating Income	-$164.15M	-$161.20M	-$233.35M	-$268.13M	-$262.88M	$159.98M	-$119.23M	-$149.00M	$88.10M	-$75.89M	-$65.34M
Depreciation & Amortization	$15.37M	$15.62M	$16.21M	$17.32M	$12.91M	$9.56M	$8.41M	$7.15M	$3.98M	$2.69M	$544.0K
EBITDA	-$148.78M	-$145.58M	-$217.13M	-$250.81M	-$249.97M	$169.54M	-$110.83M	-$141.85M	$92.08M	-$73.20M	-$64.80M
Net Income	-$196.43M	-$193.88M	-$227.10M	-$263.49M	-$280.32M	$127.84M	-$111.25M	-$94.73M	$99.94M	-$73.17M	-$62.97M
EPS (Diluted)	n/a	-$3.76	-$4.59	-$6.02	-$6.50	$2.91	-$2.98	-$2.58	$2.73	-$2.45	-$2.38
Total Assets	$386.62M	$453.03M	$465.99M	$573.97M	$833.27M	$1.11B	$708.16M	$497.91M	$543.81M	$198.68M	$172.73M
Total Liabilities	$314.85M	$350.30M	$206.34M	$262.23M	$317.07M	$349.61M	$330.41M	$47.71M	$34.97M	$15.65M	$10.99M
Shareholders' Equity	$71.77M	$102.73M	$259.65M	$311.74M	$516.20M	$764.30M	$377.75M	$450.20M	$508.85M	$183.03M	$161.74M
Cash & Equivalents	$36.49M	$34.47M	$57.53M	$34.52M	$96.95M	$345.21M	$338.43M	$69.51M	$75.56M	$46.66M	$24.84M
Operating Cash Flow	-$246.67M	-$123.96M	-$173.12M	-$218.41M	-$207.49M	$218.88M	-$54.06M	-$107.70M	$104.65M	-$57.99M	-$48.56M
Capital Expenditures	$2.99M	$2.41M	$2.44M	$9.96M	$30.72M	$84.17M	$26.87M	$11.72M	$13.28M	$7.16M	$8.15M
Free Cash Flow	-$249.67M	-$126.38M	-$175.56M	-$228.37M	-$238.21M	$134.70M	-$80.93M	-$119.42M	$91.37M	-$65.15M	-$56.71M
Shares Outstanding	54.16M	50.89M	49.55M	44.05M	43.30M	42.83M	37.48M	36.99M	36.12M	31.30M	26.48M
Weighted Average Diluted Shares	n/a	51.57M	49.51M	43.73M	43.15M	43.91M	37.28M	36.69M	36.65M	29.88M	26.41M
EPS (Basic)	n/a	-$3.76	-$4.59	-$6.02	-$6.50	$3.01	-$2.98	-$2.58	$2.99	-$2.45	-$2.38

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView